No Data
No Data
Express News | HC Wainwright & Co. Reiterates Buy on Biora Therapeutics, Maintains $15 Price Target
Biora Therapeutics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 07/22/2024 2015.95% HC Wainwright & Co. $15 → $15 Reiterates Buy → Buy 05/16/2024 2015.95% HC Wainwright &
Biora Therapeutics Buy Rating Confirmed by Positive Phase 1 Trial Outcomes and NaviCap Technology Potential
Biora Therapeutics Advances Ulcerative Colitis Treatment With BT-600 Trial Success
Express News | Biora Therapeutics Announces Supplemental Data From Phase 1 Clinical Trial of BT-600 as Presented at Kol Event
Biora Therapeutics to Host Virtual KOL Event on NaviCap Targeted Oral Delivery Platform and Results From Phase 1 Clinical Trial of BT-600 on July 17, 2024
SAN DIEGO, July 08, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (NASDAQ:BIOR), the biotech company reimagining therapeutic delivery, today announced further details on its virtual event to be held on Wednesday,